Short answer · Medically reviewed summary · Last updated: 2026-05-08
Acute myelogenous leukemia (AML) has an estimated annual incidence of approximately 3 to 5 cases per 100,000 adults in the United States and Europe. While not classified as an ultra-rare disease, Acute myelogenous leukemia (AML) remains a complex malignancy, with true prevalence difficult to track due to the aggressive nature of the disease and varying outcomes in patient survival. What is the incidence and prevalence of Acute myelogenous leukemia (AML)? The incidence of Acute myelogenous leukemia (AML) increases significantly with age.
What is the prevalence of Acute myelogenous leukemia (AML)?
Prevalence of Acute myelogenous leukemia (AML): how many people are affected worldwide, differences by sex and region, with sources.
Acute myelogenous leukemia (AML) has an estimated annual incidence of approximately 3 to 5 cases per 100,000 adults in the United States and Europe. While not classified as an ultra-rare disease, Acute myelogenous leukemia (AML) remains a complex malignancy, with true prevalence difficult to track due to the aggressive nature of the disease and varying outcomes in patient survival.
What is the incidence and prevalence of Acute myelogenous leukemia (AML)?
The incidence of Acute myelogenous leukemia (AML) increases significantly with age. According to the National Cancer Institute’s SEER database, the median age at diagnosis is 68 years. Because Acute myelogenous leukemia (AML) is an acute condition that progresses rapidly, "prevalence" is often measured by survival rates rather than total population count, as many patients undergo intensive treatment or transition to palliative care. Current data suggests approximately 20,000 to 25,000 new cases are diagnosed annually in the U.S. alone.
Who is most affected by Acute myelogenous leukemia (AML)?
Epidemiological data shows distinct patterns regarding the patient population for Acute myelogenous leukemia (AML):
- Gender: Incidence rates are slightly higher in males compared to females.
- Age: While it can occur at any age, it is primarily a disease of older adults; pediatric cases exist but are rarer.
- Ethnicity: Some studies indicate higher incidence rates among non-Hispanic white populations compared to other ethnic groups, though this is an area of ongoing research.
Why is accurate data for Acute myelogenous leukemia (AML) challenging to capture?
Tracking the exact number of people living with Acute myelogenous leukemia (AML) is difficult due to the heterogeneity of the disease. Subtypes defined by specific genetic mutations mean that clinical experiences vary wildly. Furthermore, 62 individuals within the DiseaseMaps.org community have shared their personal experiences, providing a crucial, real-world layer of data that helps bridge the gap between cold clinical statistics and the lived reality of patients navigating this diagnosis.
Next steps
- Consult a hematologist-oncologist to discuss specific genetic markers and treatment protocols.
- Connect with the 62 members of the DiseaseMaps.org community to share experiences and coping strategies.
- Inquire about clinical trials through the Leukemia & Lymphoma Society or your regional cancer center.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.
References
- National Cancer Institute (NIH) – SEER Cancer Statistics Review
- Orphanet – Rare Disease Database (ORPHA:519)
- The Leukemia & Lymphoma Society (LLS) – AML Facts and Statistics
- American Cancer Society – Key Statistics for Acute Myeloid Leukemia
